Molecular Partners AGMLLCF 25 Debt-to-EBITDA is -0.07 as of Mar. 2026. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 290 Biotechnology companies, Molecular Partners AG ranks worse than 344827.24% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Molecular Partners AG's Debt-to-EBITDA or its related term are showing as below:
MLLCF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.12 Med: -0.06 Max: 0.04
Current: -0.06
During the past 13 years, the highest Debt-to-EBITDA Ratio of Molecular Partners AG was 0.04. The lowest was -0.12. And the median was -0.06.
MLLCF's Debt-to-EBITDA is ranked worse than 100% of 290
companies
in the Biotechnology industry
Industry Median: 1.15
vs MLLCF: -0.06
Molecular Partners AG (OTCPK:MLLCF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Molecular Partners AG Debt-to-EBITDA Related Terms
Molecular Partners AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLLCF vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Molecular Partners AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Molecular Partners AG (MLLCF) has a Debt-to-EBITDA of -0.07 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Molecular Partners AG. According to the industry distribution chart, Molecular Partners AG ranks #999999 out of 290 companies in the Biotechnology industry.
Is Molecular Partners AG's Debt-to-EBITDA too high?
Molecular Partners AG's current Debt-to-EBITDA is -0.07. Based on the distribution chart, Molecular Partners AG ranks #999999 out of 290 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #999999 out of 290 companies for Debt-to-EBITDA. This places Molecular Partners AG in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 290 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Molecular Partners AG. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Debt-to-EBITDA is -0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $3.60 — trading 605.9% above its estimated fair value. The current Debt-to-EBITDA is -0.07. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Debt-to-EBITDA is -0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.60 is trading 605.9% above its estimated GF Value™ of $0.51.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Debt-to-EBITDA: -0.07
GF Value™: $0.51 vs. price of $3.60 (605.9% above fair value)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
